CPHD

CPHD - Cephid

NASDAQ

Add Alert

CPHD

CPHD - Cephid

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

stocktrademan Free

06/05/14 1:55 PM

Post #27

cphd call calendars

jun/jul 45 at 1.45 (max gain .6056/1.45 = 41.8%, b/e 46.38 43.67)
jul/sep 45 at 1.15 (max gain 1.637/1.15 = 142.3% b/e 49.89 41.00)

X columns on a downtrend may indicate sideways/retracement price action

$CPHD

DD Notes ~ http://www.ddnotesmaker.com/CPHD

##### recent news/filings ~ source: finance.yahoo.com

Tue, 27 May 2014 12:37:47 GMT ~ Cepheid upgraded at Needham
[at theflyonthewall.com] - Cepheid upgraded at Needham
read full: http://www.theflyonthewall.com/permalinks/entry.php/CPHDid2016130/CPHD-Cepheid-upgraded--at-Needham
*********************************************************

Tue, 27 May 2014 10:39:02 GMT ~ Cepheid upgraded to Buy from Hold at Needham
[at theflyonthewall.com] - Cepheid upgraded to Buy from Hold at Needham
read full: http://www.theflyonthewall.com/permalinks/entry.php/CPHDid2016036/CPHD-Cepheid-upgraded-to-Buy-from-Hold-at-Needham
*********************************************************

Tue, 27 May 2014 10:24:54 GMT ~ Cepheid upgraded by Needham
read full: http://finance.yahoo.com/q/ud?s=CPHD
*********************************************************

Fri, 23 May 2014 20:48:07 GMT ~ Cepheid: Updated Research Report
read full: http://finance.yahoo.com/news/cepheid-updated-research-report-204807606.html
*********************************************************

Thu, 22 May 2014 20:05:00 GMT ~ Cepheid to Webcast Upcoming Financial Presentations
[PR Newswire] - SUNNYVALE, Calif., May 22, 2014 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast. ...
read full: http://finance.yahoo.com/news/cepheid-webcast-upcoming-financial-presentations-200500464.html
*********************************************************

##### chart ~ source: stockcharts.com

##### chart ~ source: eoddata.com

##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CPHD/company-info
Ticker: $CPHD
OTC Market Place: Not Available
CIK code: 0001037760
Company name: Cepheid
Incorporated In: CA, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001037760&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/CPHD/filings
Latest financials: http://www.otcmarkets.com/stock/CPHD/financials
Latest news: http://www.otcmarkets.com/stock/CPHD/news - http://finance.yahoo.com/q/h?s=CPHD+Headlines

Major holdings: http://data.cnbc.com/quotes/CPHD/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=CPHD+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/CPHD.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=CPHD

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=CPHD&search=search

DTCC: http://search2.dtcc.com/?q=Cepheid&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Cepheid
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Cepheid&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/CPHD/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/CPHD/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/CPHD/research
Historical Prices: http://finance.yahoo.com/q/hp?s=CPHD+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=CPHD+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=CPHD+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=CPHD+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=CPHD+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=CPHD+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=CPHD
Balance Sheet: http://finance.yahoo.com/q/bs?s=CPHD
Cash Flow: http://finance.yahoo.com/q/cf?s=CPHD+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/CPHD
Bloomberg: http://www.bloomberg.com/quote/CPHD:US
Morningstar: http://quotes.morningstar.com/stock/s?t=CPHD
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CPHD
Barchart: http://www.barchart.com/quotes/stocks/CPHD
OTC Short Report: http://otcshortreport.com/index.php?index=CPHD
Investopedia: http://www.investopedia.com/markets/stocks/CPHD/?wa=0

http://www.pennystocktweets.com/stocks/profile/CPHD

##### last known share structure ~ source: otcmarkets.com

Market Value: $3,060,201,985 a/o Jun 04, 2014
Shares Outstanding: 69,724,356 a/o Apr 22, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com

DD Notes ~ http://www.ddnotesmaker.com/CPHD

Penny Roger$ Free

04/19/12 11:53 AM

Post #26

Re: #25: @Penny Roger$ - ~ Thursday! $CPHD ~ Q1 Earnings posted, pending

Penny Roger$ Free

04/19/12 11:52 AM

Post #25

~ Thursday! $CPHD ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CPHD ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=CPHD&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=CPHD&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=CPHD
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CPHD#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CPHD+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CPHD
Finviz: http://finviz.com/quote.ashx?t=CPHD
~ BusyStock: http://busystock.com/i.php?s=CPHD&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=CPHD >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

surf1944

03/20/12 8:23 AM

Post #24

7:24AM On The Wires (WIRES) : Cepheid (CPHD) announced that, together with the University of Medicine and Dentistry of New Jersey , it has received a grant from the National Institutes of Health to develop sample processing and amplification methods for detection of bloodstream bacteria using nested polymerase chain reaction on the GeneXpert System. The $1.3 mln grant is for the first year of an expected five-year, $5.5 mln program.

RonnieD

04/25/09 1:44 PM

Post #23

biothreat picking up with swine flu.

CPHD in play

http://finance.yahoo.com/q?s=CPHD&.yficrumb=zt%2FgxI3C9vT

Golden Cross PremiumMember

06/01/06 7:37 AM

Post #22

Cepheid Launches CE Mark Certification Smart VZV(TM) in Vitro Diagnostic Test for SmartCycler(R) Platform
Thursday June 1, 7:00 am ET
Real-Time PCR Test for Varicella Zoster-Virus Detection Provides Improved Diagnosis and Patient Treatment

SUNNYVALE, Calif., June 1 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), a broad-based molecular diagnostics company, today announced the European release of the Smart VZV(TM) Assay for clinical diagnostic use on the SmartCycler® System. The VZV assay was released as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Smart VZV is intended for rapid detection of the varicella-zoster virus, a member of the herpes virus subfamily, the cause of potentially life-threatening complications of the lungs, liver and central nervous system in immunocompromised children. The virus can also cause serious eye, kidney and brain infections also known as retinitis, acute renal necrosis and chronic progressive encephalitis respectively in HIV patients. In addition, VZV the cause of herpes zoster (shingles), may be confused with herpes simplex virus and appropriate laboratory tests are often required for support of the correct diagnosis and subsequent treatment.
ADVERTISEMENT

"Multiple data indicate that PCR analysis is more efficient than antigen or antibody testing or viral culture. Now swab specimens obtained from skin and mucosa in addition to cerebrospinal fluid of patients with aseptic meningitis and encephalitis can be used for rapid and sensitive detection of varicella-zoster virus (VZV) via real time PCR," said Professor Jacques Izopet, Head of the Clinical Virology Laboratory, University Hospital of Toulouse. "The results are highly relevant for optimization of specific antiviral therapy for these patients."

"The Smart VZV test is the fourth in a planned menu of CE IVD Mark products scheduled to be released in Europe for use on our SmartCycler and GeneXpert® platforms during 2006 and is the second product in our expanding portfolio for use in the management of immunocompromised patients," said Cepheid Chief Executive Officer John Bishop.

Real-time PCR is a reliable tool for detection of VZV in patients who have developed or are at risk for developing active VZV infection. PCR is especially important in cerebrospinal fluid (CSF) samples where standard viral culture procedures are relatively insensitive. The Smart VZV Assay offers a standardized qualitative method that can be used for the detection of VZV DNA in vesicle swabs and CSF samples. The assay offers a highly sensitive limit of detection. The use of an internal control greatly minimizes the risk of false negative results.

Cepheid's Smart VZV delivers a positive or negative result in under an hour after DNA extraction, a dramatic improvement over the days required to derive a result with traditional culture-based tests.

The SmartCycler® System is a leading real-time PCR testing platform for hospitals, university labs and government agencies. By automating the amplification and detection process, the SmartCycler® System can deliver highly accurate and consistent test results from prepared biological samples in 30-40 minutes. With up to 96 independently programmable reaction sites, the SmartCycler can simultaneously run multiple experiments with different protocols and at different times. This eliminates complex advanced scheduling on larger, more costly systems as well as the need to transport samples to central facilities for analysis.

About Cepheid

Cepheid (Nasdaq: CPHD - News), based in Sunnyvale, Calif., is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and timing of product shipments and expansion in the clinical diagnostics market. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: development and manufacturing problems; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; customer acceptance of new products; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2005 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS:
At the Company:
John L. Bishop John R. Sluis
CEO, Cepheid CFO, Cepheid
408-541-4191 408-541-4191
john.bishop@cepheid.com john.sluis@cepheid.com

At Financial Relations Board: At Schwartz Communications:

Tricia Ross Chris Stamm / Tom Bain
Investor/Analyst Information 781-684-0770
617-520-7064 cepheid@schwartz-pr.com

Golden Cross PremiumMember

05/23/06 8:13 AM

Post #21

Re: #20: @Golden Cross - Cepheid Introduces GeneXpert(R) 16-Site System

FIND and Cepheid to Develop Rapid TB Test for Developing Nations
Tuesday May 23, 7:00 am ET
GeneXpert(R) System Uniquely Suited to Bring Sophisticated Molecular Diagnostics to the Third World; Improved Detection Essential in Fighting This Lethal Infectious Disease

SUNNYVALE, Calif. and GENEVA, May 23 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), a broad-based molecular diagnostics company, today announced a collaboration with the Foundation for Innovative Diagnostics (FIND), a Geneva-based non-profit organization, to develop a new, rapid molecular diagnostic test for tuberculosis (TB). Funded by the Bill and Melinda Gates Foundation, FIND is dedicated to identifying and applying the latest biotechnology innovations to develop affordable diagnostic tests for diseases affecting underprivileged populations in developing countries. Dr. David Alland, an expert in the field of tuberculosis, and his research group at the University of Medicine and Dentistry of New Jersey will also be collaborating with Cepheid in developing the test to rapidly detect TB mycobacteria in sputum and simultaneously determine whether the organisms are drug resistant. The test will be designed to run on Cepheid's GeneXpert® System.
ADVERTISEMENT

There is an urgent need for more accurate and cost-effective diagnostic technologies for diseases of the developing world -- particularly TB. A chronic bacterial infection, TB caused an estimated 1.7 million deaths in 2004 according to World Health Organization (WHO) data. The spread of TB has been exacerbated by the large number of global travelers, worldwide rise of multidrug-resistant TB strains, and the global spread of HIV which markedly increases susceptibility to tuberculosis. Immunodeficient HIV-positive patients are particularly vulnerable to TB, which is reported to account for the deaths of 13 percent of patients in this group worldwide.

"Without easy to use diagnostics, too many TB cases go undetected and the disease continues to kill nearly 2 million people a year," said Dr. Giorgio Roscigno, CEO of FIND. "This collaboration will enable us to harness sophisticated molecular technology to develop an affordable and user-friendly test that can detect TB and its drug-resistant forms."

Developed a century ago, today's standard culture method for TB detection takes several weeks to generate results and is frequently inaccurate. Lack of effective diagnostics contributes to the worldwide TB problem, as untreated TB patients remain a source of infection for other members of the community. Current molecular diagnostic detection methods for TB are faster and more accurate than culture, but they are not practical to implement in developing countries which lack the specialized laboratories and highly trained technicians required to run the tests. In addition, these methods do not offer on-demand testing, an important feature for TB control.

"Cepheid is honored to share its technical expertise in molecular diagnostics and its unique testing platform with FIND to develop a solution for this global health problem," said Cepheid CEO, John Bishop. "Through the ability of the GeneXpert System to uniquely automate the otherwise complicated real-time PCR processes, sophisticated, on-demand molecular diagnostics can be brought to nations where highly trained staff and dedicated facilities are in short supply."

Mark Perkins, Chief Scientific Officer of FIND, said, "today's standard methods for detecting multidrug-resistant TB (MDR TB), which cannot be cured with conventional treatment, require several months to yield results. During this time, patients get sicker or die and pass the infection along to others in the community. This technology can simplify molecular detection of MDR-TB and make early diagnosis possible."

Representing a paradigm shift in the automation of molecular diagnostics, the GeneXpert System is the only closed, self-contained, fully-integrated and automated system for molecular testing commercially available today. The system will allow healthcare providers to obtain timely, accurate results from virtually any type of raw biological sample, with minimal risk of contamination. The easy to use system is designed to operate in a wide range of environments, including hospitals, public health clinics, physician offices, and industrial settings as applicable.

About FIND

The Foundation for Innovative New Diagnostics (FIND) is a non-profit foundation dedicated to the development and introduction of simple, accurate, reliable and accessible diagnostic tools for poverty related infectious diseases in the developing world. Since its launch at the World Health Assembly in 2003, FIND's initial focus has been on identifying new tools for the diagnosis of tuberculosis. FIND is also collaborating with the World Health Organization for development and evaluation of new diagnostic tests for human African trypanosomiasis, also known as sleeping sickness, and is planning to introduce into its project profile a program to improve malaria diagnostics. FIND is located in Geneva, Switzerland. For more information, please visit www.finddiagnostics.org.

About Cepheid

Cepheid (Nasdaq: CPHD - News), based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See www.cepheid.com for more information.

Golden Cross PremiumMember

05/23/06 1:54 AM

Post #20

Cepheid Introduces GeneXpert(R) 16-Site System
Monday May 22, 7:00 am ET
Modular High-Throughput GeneXpert System is the First Fully-Integrated, Closed, On-demand Molecular Methods System

ORLANDO, ASM ANNUAL MEETING (BOOTH #701), May 22 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), a broad-based molecular diagnostics company, today introduced the GeneXpert® 16-Site System at the 106th Annual Meeting of the American Society for Microbiology. The latest addition to Cepheid's GeneXpert® family of real-time PCR (polymerase chain reaction) devices provides a high-throughput, fully-automated solution to deliver results quickly and efficiently to hospitals and laboratories.
ADVERTISEMENT

While current molecular methods deliver highly sensitive, specific and rapid results compared to culture-based approaches, molecular biology labs generally run tests when a sufficient number of samples is reached to justify processing a batch. As a result, even though time of analysis is minutes or hours, effective turnaround time is often a day or more depending on the test. Batch processing is no longer the only option, as Cepheid's GeneXpert 16-Site System has the flexibility to run up to 16 different molecular tests simultaneously, with minimal hands-on time, thereby delivering the power of true on-demand testing. The GeneXpert System is expected to provide the molecular laboratory with the ability to start test runs anytime samples are collected-24 hours a day, 365 days a year.

"Cepheid's GeneXpert technology represents a true paradigm shift in the practical implementation of real-time PCR," said Cepheid CEO John Bishop. "No longer limited by batch processing protocols and laborious manual procedures, laboratorians can now have access to critical answers when they need them. In addition, laboratories will have a unique ability to run the exact same tests on a high through-put main lab system or on a desktop system in a satellite lab."

Cepheid's GeneXpert Systems are the first to combine sample preparation with real time PCR amplification and detection functions for fully integrated and automated nucleic acid analysis. The system purifies, concentrates, detects and identifies targeted nucleic acid sequences, delivering results in as little as one to two hours from unprocessed specimens.

The GeneXpert® 16-Site System is configurable from 4 to16 modules, allowing users to expand their system as demand for assays increase. The system boasts full random access capabilities performing multiple molecular tests simultaneously. The automated software eliminates the need for interpretation by users, which enables the laboratory to be more efficient with more tests.

Availability

Shipments of the GeneXpert 16-Site System are expected to begin in the 4th quarter of 2006. The system will support the current menu of tests available on the GeneXpert 4-Site System and all GeneXpert tests in the product pipeline.

About Cepheid

Cepheid (Nasdaq: CPHD - News), based in Sunnyvale, Calif., is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See www.cepheid.com for more information.

Golden Cross PremiumMember

05/02/06 7:30 AM

Post #19

Cepheid to Present at Robert W. Baird & Co. 2006 Growth Stock Conference
Tuesday May 2, 7:00 am ET

SUNNYVALE, Calif., May 2 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News) will present at the Robert W. Baird & Co. 2006 Growth Stock Conference being held at the Four Seasons Hotel, Chicago, Illinois, May 9-11, 2006. Chief Executive Officer John L. Bishop and Senior Vice President, Finance and Chief Financial Officer, John R. Sluis will present at 1:55p.m. Central on Tuesday, May 9, 2006.
ADVERTISEMENT

Robert W. Baird & Co. will provide a live webcast of the audio presentation available at the following address: http://wsw.com/webcast/rwbaird14/cphd/. The webcast, along with accompanying presentation slides, may also be accessed on the Company's web site at www.cepheid.com under Investors: Events: Webcasts and Presentations. A replay of the webcast presentation will be available for 90 days.

Golden Cross PremiumMember

03/22/06 11:10 AM

Post #18

Re: #17: @SlateColt - What are the implications of this, if any?

Much more exposure for the company = Sales..or potential sales...It is a win win for the company...JMHO and GLTY

SlateColt

03/22/06 11:00 AM

Post #17

Re: #16: @Golden Cross - Cepheid GeneXpert(R) System Receives Department of Homeland Security Certification

What are the implications of this, if any?

Golden Cross PremiumMember

03/22/06 7:33 AM

Post #16

Cepheid GeneXpert(R) System Receives Department of Homeland Security Certification
Wednesday March 22, 7:00 am ET
SAFETY Act Designation Makes GeneXpert Biothreat Solutions More Accessible to Organizations Across the United States

SUNNYVALE, Calif., March 22 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), a broad-based molecular diagnostics company, announced today that it has received both certification and designation of the GeneXpert® technology as Qualified Anti-terrorism Technology (QATT). GeneXpert is now listed among products approved by the Department of Homeland Security and is granted coverage under the Support Anti-Terrorism by Fostering Effective Technology Act known as the SAFETY Act.
ADVERTISEMENT

The SAFETY Act encourages the development and deployment of anti-terrorism technologies that will substantially enhance the protection of the nation. The Act reflects the intent of Congress to ensure the threat of liability does not deter potential sellers from developing and commercializing technologies that could significantly reduce the risk or mitigate the effect of terrorist acts. It creates certain liability limitations when QATTs have been deployed but does not limit liability where an act of terrorism has not occurred.

"All Cepheid suppliers, vendors, and customers benefit from the protection of SAFETY Act Certification knowing that the GeneXpert System meets the government's most stringent standards for biothreat technology," said Cepheid Chief Executive Officer John Bishop. "The GeneXpert technology has been demonstrated to be an accurate and effective solution to meeting varying needs in the potential detection of biothreat agents."

Cepheid's GeneXpert is the world's only system to combine sample preparation with real time PCR (polymerase chain reaction) amplification and detection -- delivering fully-integrated and automated DNA analysis. The system purifies, concentrates, detects and identifies targeted nucleic acid sequences, delivering answers from unprocessed samples in minutes. Current techniques for performing the same complex sample prep and PCR procedures involve skilled technicians in microbiology labs performing manual tasks that can take more than a day to complete. No specialized facilities or highly skilled laboratory training is required to operate the GeneXpert System.

Golden Cross PremiumMember

03/02/06 12:19 AM

Post #15

Form 8-K for CEPHEID

--------------------------------------------------------------------------------

1-Mar-2006

Other Events, Financial Statements and Exhibits

ITEM 8.01. OTHER EVENTS.
On March 1, 2006, Cepheid issued a press release announcing that it had submitted its Xpert GBSTM test for Group B Streptococcus (GBS) for use on the GeneXpert System to the U.S. Food & Drug Administration for regulatory clearance. A copy of the press release is attached as Exhibit 99.01 to this current report on Form 8-K and is incorporated by reference herein.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
Number Description
99.01 Press release dated March 1, 2006

Golden Cross PremiumMember

02/23/06 7:13 AM

Post #14

Re: #13: @Golden Cross - Shares Outstanding: 42.64M

Total Cash (mrq): 40.25M
Total Cash Per Share (mrq): 0.944

Golden Cross PremiumMember

02/23/06 7:13 AM

Post #13

Re: #12: @Golden Cross - Cepheid and the Public Health Agency of Canada

Shares Outstanding: 42.64M
Float: 40.73M
% Held by Insiders4: 9.51%
% Held by Institutions4: 47.80%

Golden Cross PremiumMember

02/23/06 7:12 AM

Post #12

Re: #11: @Golden Cross - Cepheid Initiates CE IVD Products in Europe With

Cepheid and the Public Health Agency of Canada to Collaborate on Development of In-Field Nucleic Acid Detection Tests for Category 1 and 2 Biological Agents
Tuesday February 14, 7:00 am ET

SUNNYVALE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News) today announced that it has entered into a collaboration with the Public Health Agency of Canada's National Microbiology Laboratory to develop in-field nucleic acid assays for Ebola, Marburg and Lassa fever viruses utilizing Cepheid's GeneXpert technology. Under the agreement, Cepheid and the Public Health Agency of Canada's National Microbiology Laboratory have been awarded $780,000 Canadian over a 2 year period to develop the assays. The GeneXpert was chosen for this project because of its ability to both process samples and run PCR in a field environment.

ADVERTISEMENT
"This program represents a unique opportunity as we execute our strategy to broaden Cepheid's Biothreat test menu. There are only a few labs in the world where these organisms can be handled. We look forward to working with Canada's Public Health Agency National Microbiology Laboratory in moving the program to a successful completion," said John Bishop Cepheid's Chief Executive Officer.

The grants funding this program are coming from the Chemical, Biological, Radiological and Nuclear (CBRN) Research and Technologies Initiative (CRTI) in Canada. CRTI is a Canadian interdepartmental initiative comprised of 14 government science-based and security departments and agencies. Funding allocation for CRTI projects requires that a commercial partner is involved so that the funding results in a product. Cepheid will retain rights to the developed technology along with product distribution rights.

Golden Cross PremiumMember

02/23/06 7:11 AM

Post #11

Re: #10: @Golden Cross - First Responders Select GeneXpert System for Biothreat Detection

Cepheid Initiates CE IVD Products in Europe With Launch of GeneXpert(R) System and Xpert BCR-ABL Monitor(TM) Assay
Thursday February 23, 7:00 am ET

SUNNYVALE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), a broad-based molecular diagnostics company, today announced the European launch of the GeneXpert® System for in vitro diagnostic use (IVD) along with the Xpert BCR-ABL Monitor(TM) assay, the initial clinical diagnostic test for use on the GeneXpert® System. Both the GeneXpert System and the Xpert BCR-ABL Monitor assay were released as "Conformite Europeene" or "European Conformity" CE IVD Mark products under the European Directive on In Vitro Diagnostic Medical Devices. The Xpert BCR-ABL Monitor can be used by hematologist-oncologists and labortorians as an aid in the monitoring of BCR-ABL, an abnormal genetic marker found in patients with Chronic Myelogenous Leukemia (CML).

ADVERTISEMENT
"The GeneXpert® System has been demonstrated to be robust, easy to use and capable of delivering sensitivity and specificity not previously seen in molecular testing," said John Bishop, Cepheid CEO. "In the European clinical molecular diagnostics market the ability of the clinician to obtain immediately actionable intelligence is critical to patient management. We believe the GeneXpert® System is in a unique position to deliver on this clinical need."

The GeneXpert System and the Xpert BCR-ABL Monitor assay is the world's first closed system, quantitative, nested real-time PCR (polymerase chain reaction) assay. This assay allows healthcare providers in Europe to obtain timely, near-patient, highly sensitive and accurate results from a blood sample, with minimal potential for RNA loss or sample contamination. The GeneXpert System combines sample preparation with real time nested PCR amplification and detection for fully-automated DNA and RNA analysis. The system purifies, concentrates, detects and identifies targeted nucleic acid sequences. The BCR-ABL assay provides in approximately 2 hours. Current techniques for performing the same complex sample prep, reverse transcription, and PCR procedures involve skilled technicians in centralized molecular labs performing batched manual tasks that can take two to three days to complete.

Chronic myelogenous leukemia (CML) is part of a group of diseases called myeloproliferative disorders. There are approximately 20,000 CML patients living in remission in Europe today. Current Europe Against Cancer Program practice guidelines for management of patients with CML call for use of quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) assays during the initial workup of patients with chronic phase CML and in monitoring for minimal residual disease, and in identifying patients who may be at a high risk for relapse. Patients may have their blood tested as many as four times a year.

The GeneXpert® System is currently the only real-time PCR platform that integrates microfluidic sample preparation with the sensitivity of real-time polymerase chain reaction (PCR) based molecular detection resulting in the first easy-to-use system in this field. The GeneXpert® System was released in the Biothreat surveillance market in 2004 and has subsequently been proven to be an extremely robust and accurate platform technology with over 1,100 modules and systems in the market generating over 2.1 million anthrax test results.

About Cepheid

Golden Cross PremiumMember

02/23/06 7:11 AM

Post #10

First Responders Select GeneXpert System for Biothreat Detection
Thursday February 16, 7:00 am ET
Detroit & Honolulu Emergency First Response Teams Use GeneXpert System to Provide Accuracy & Specificity of Molecular Diagnostics for Biothreat Detection

SUNNYVALE, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), a broad-based molecular diagnostics company, today announced that the State Regional Hazmat Response Team (Oakland County, MI) and the City and County of Honolulu, Hawaii's Bio-Weapon Illness Prevention Program and EMS Medical Strike Team selected the GeneXpert® System to provide mobile Anthrax detection.

ADVERTISEMENT
"As more than 100,000 visitors traveled to the Detroit metro area this month, the State Regional Hazmat Response Team needed a solution to investigate potential biothreat attacks delivering accurate results in minutes, not hours," said Gary Sharp of the Independence Fire Department. "The GeneXpert® System proved to be the ideal solution. Non-scientific personnel can operate the test and easily read the result, obtaining fast, accurate information to make informed decisions on scene."

The GeneXpert System combines sample preparation with real time PCR (polymerase chain reaction) amplification and detection for fully-automated DNA analysis. The system purifies, concentrates, detects and identifies targeted nucleic acid sequences, delivering answers from unprocessed samples in minutes. Current techniques for performing the same complex sample prep and PCR procedures involve skilled technicians in microbiology labs performing manual tasks that can take more than a day to complete.

"Whether it's protecting a major sporting event at Aloha Stadium or patrolling popular tourist sites, the Honolulu EMS Medical Strike Team is on call twenty four hours a day, seven days a week to protect citizens and visitors from potential biothreat attacks," said Cortney M. Chambers, Homeland Security Coordinator for Honolulu Emergency Medical Services. "GeneXpert is an important addition to our mobile laboratory -- it's an effective way to bring a sophisticated molecular diagnostics lab to the investigation scene."

In addition to its use with emergency first responder units, GeneXpert Anthrax tests are currently in use at the United States Postal Service where over 2.1 million tests have already been run. In addition to the GeneXpert Anthrax test, an expanded menu of tests for other biothreat agents is under development.

"The GeneXpert System has demonstrated itself to be a capable tool in the nation's fight against biological terrorism, but it is more than a biothreat detection system," said Cepheid CEO John Bishop. "The GeneXpert System is expected to deliver in the near future immediately actionable results to medical professionals as well. Last October, Cepheid launched the GeneXpert BCR-ABL RUO product. For research use only, the product identifies the BCR- ABL chromosomal translocation associated with Chronic Myelogenous Leukemia in the clinical research laboratory. This product is expected to be complemented later this year by the introduction of several clinical diagnostic tests for medical conditions where a timely diagnosis is critical to patient care."

Golden Cross PremiumMember

02/23/06 7:10 AM

Post #9

Re: #8: @Golden Cross - CPHD Cepheid Initiates CE IVD Products in Europe

Cepheid Q4 loss widens
Wed Feb 22, 2006 6:03 PM ET

(Adds 2006 forecast)

Feb 22 (Reuters) -

CEPHEID (CPHD.O: Quote, Profile, Research)

Latest Forecast* No. of Yr ago

analysts qtr Loss (diluted, $/shr) 0.08 0.06 2 0.07 Net loss ($ million) 3.2 -- -- 3.0 Total revenue ($ million) 23.6 22.1 2 20.3

*Source: Reuters Estimates

--The company, which makes systems for genetic analysis said in 2006 it expects to post a net loss of $7.0 million to $9.0 million, or 16 cents to 21 cents a share.

--Excluding the effect of change in accounting for stock option expense, the company said it expects to post an operating profit during the year.

--According to Reuters Estimates, two analysts on average expect the company to post a loss of 20 cents a share, excluding exceptional items, in 2006. (Reporting by Kenan Machado and Anant Vijay Kala in Bangalore)

FACT BOX
CPHD.O
Last: $9.71
Change: +0.14
Up/Down: +1.46%

MarJunSepDec

Quote
Full Chart
Company Profile
Analyst Research
Click here to find out more!

Golden Cross PremiumMember

02/23/06 7:08 AM

Post #8

CPHD Cepheid Initiates CE IVD Products in Europe With Launch of GeneXpert(R) System and Xpert BCR-ABL Monitor(TM) Assay
PR Newswire - February 23, 2006 7:01 AM (EDT)

SUNNYVALE, Calif., Feb 23, 2006 /PRNewswire-FirstCall via COMTEX/ -- Cepheid (Nasdaq: CPHD), a broad-based molecular diagnostics company, today announced the European launch of the GeneXpert(R) System for in vitro diagnostic use (IVD) along with the Xpert BCR-ABL Monitor(TM) assay, the initial clinical diagnostic test for use on the GeneXpert(R) System. Both the GeneXpert System and the Xpert BCR-ABL Monitor assay were released as "Conformite Europeene" or "European Conformity" CE IVD Mark products under the European Directive on In Vitro Diagnostic Medical Devices. The Xpert BCR-ABL Monitor can be used by hematologist-oncologists and labortorians as an aid in the monitoring of BCR-ABL, an abnormal genetic marker found in patients with Chronic Myelogenous Leukemia (CML).

"The GeneXpert(R) System has been demonstrated to be robust, easy to use and capable of delivering sensitivity and specificity not previously seen in molecular testing," said John Bishop, Cepheid CEO. "In the European clinical molecular diagnostics market the ability of the clinician to obtain immediately actionable intelligence is critical to patient management. We believe the GeneXpert(R) System is in a unique position to deliver on this clinical need."

The GeneXpert System and the Xpert BCR-ABL Monitor assay is the world's first closed system, quantitative, nested real-time PCR (polymerase chain reaction) assay. This assay allows healthcare providers in Europe to obtain timely, near-patient, highly sensitive and accurate results from a blood sample, with minimal potential for RNA loss or sample contamination. The GeneXpert System combines sample preparation with real time nested PCR amplification and detection for fully-automated DNA and RNA analysis. The system purifies, concentrates, detects and identifies targeted nucleic acid sequences. The BCR-ABL assay provides in approximately 2 hours. Current techniques for performing the same complex sample prep, reverse transcription, and PCR procedures involve skilled technicians in centralized molecular labs performing batched manual tasks that can take two to three days to complete.

Chronic myelogenous leukemia (CML) is part of a group of diseases called myeloproliferative disorders. There are approximately 20,000 CML patients living in remission in Europe today. Current Europe Against Cancer Program practice guidelines for management of patients with CML call for use of quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) assays during the initial workup of patients with chronic phase CML and in monitoring for minimal residual disease, and in identifying patients who may be at a high risk for relapse. Patients may have their blood tested as many as four times a year.

The GeneXpert(R) System is currently the only real-time PCR platform that integrates microfluidic sample preparation with the sensitivity of real-time polymerase chain reaction (PCR) based molecular detection resulting in the first easy-to-use system in this field. The GeneXpert(R) System was released in the Biothreat surveillance market in 2004 and has subsequently been proven to be an extremely robust and accurate platform technology with over 1,100 modules and systems in the market generating over 2.1 million anthrax test results.

brainlessone PremiumMember

12/02/02 4:04 PM

Post #7

can anyone prepare a cogent 8 month forward valuation of this company?

I think the introduction of the smartcycler ii and the strep kit is likely to double sales going forward, so we will see about 25 million in sales next year. If the postal contract is signed forward this will also boost sales. but at 1.5 million a month burn, this will likely just get to break even with increasing sales. The red herring or gold herring is the continued introduction of tests by IBI and geneexpert introduction, and foreign sales which are only starting to get adequately marketed.

an increase of 1000 units a year would mean a very large jump in sales

what is a normal ratio of market cap to forward sales?

DUCKY

11/29/02 11:21 AM

Post #6

Hi eve you there? WEEEEEEEEEE GO CPHD

jmhollen

05/09/02 9:51 AM

Post #5

$3.4 Million to Support Applications for Diagnostics and Bio-Threat Detection

SUNNYVALE, Calif., May 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD)
today announced the United States Army Medical Research Institute of
Infectious Diseases (USAMRIID) has expanded the scope and funding for its
development contract by $3.4 million over the next two years. Under this
contract, Cepheid will develop biochemical reagents used in the detection of
bio-threat agents and other pathogens, as well as develop various protocols,
processes and assays for Cepheid's fully automated GeneXpert(R) DNA detection
system.

The contract's key deliverables call on Cepheid to expand applications of
the GeneXpert for integrated sample preparation and detection of viruses in
biological samples, develop nine prototype assays using Cepheid's proprietary
dry-bead reagent formulation, develop protocols and tools to detect sepsis
with the GeneXpert, and establish a multiplex assay to distinguish the
virulent form of anthrax from other non-virulent anthrax species in a single
test.

"During the height of the anthrax crisis last year, we made extensive use
of Cepheid's Smart Cycler(R) instruments and DNA detection technology to
rapidly identify anthrax in powders and letters and to confirm the genetic
identity of cultured Bacilli isolated during environmental assessments of
contaminated areas in New York and Washington," said Colonel Erik A. Henchal,
U.S. Army Medical Services Corps and Chief of the Diagnostic Systems Division
at USAMRIID. "With the added capability of automated sample preparation, the
GeneXpert will further enhance our ability to handle a variety of biological
samples in time-critical testing scenarios."
Kurt Petersen, Ph.D., Cepheid's president and chief operating officer
added, "As the lead medical research laboratory for the U.S. Biological
Defense Research Program, the rapid detection of infectious disease is central
to USAMRIID's mission and has been the focusof our shared vision over the
past five years. We are gratified that USAMRIID has extended their development
contract with us for infectious disease diagnostics."

Cepheid, based in Sunnyvale, Calif., is a leading developer, manufacturer
and marketer of miniaturized, fully integrated systems for rapid, on-site
detection of DNA -- the universal biological identifier. Founded in 1996, the
company is commercializing its technology and products for scientific, medical
and industrial applications requiring time-critical detection of human and
other genes, infectious disease agents, and industrial and environmental
contaminants at the point of need. Cepheid, Smart Cycler and GeneXpert are
registered trademarks of Cepheid. See http://www.cepheid.com for more
information.

USAMRIID is the Army's lead laboratory for developing medical products for
biological defense and is a subordinate laboratory of the U.S. Army Medical
Research and Material Command, Fort Detrick, Md.

StockTrader Grandfathered

04/25/02 11:36 AM

Post #4

Cepheid Granted U.S. Patent Covering GeneXpert(R) Cartridge

SUNNYVALE, Calif., April 25 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the issuance of U.S. Patent 6,374,684 covering the fundamental fluidic control technology that enables cartridge-based automated preparation of biological samples in the company's GeneXpert(R) DNA detection system.

"This patent is essential to Cepheid's vision to move DNA testing out of the lab and into everyday, routine use," said Kurt Petersen, Ph.D., president and chief operating officer. "The novel cartridge provides the flexibility to perform a broad range of sample preparation functions on a variety of biological samples, such as blood, urine, emulsified tissue or food, and environmental samples. At the same time, the cartridge eliminates cross-contamination between samples, between chambers in the cartridge and between the cartridge and the instrument. Such cross-contamination has been a major impediment to commercialization of DNA-based assays."

Cepheid has achieved sample-processing capability in its GeneXpert cartridge through the use of a unique valve system with an integral syringe drive that maintains a dry interface between the cartridge and the GeneXpert instrument. The Cepheid cartridge design is the fundamental technology that allows an inexperienced user to operate the GeneXpert system for DNA detection and analysis.

Automated Sample Preparation

Before a biological sample can be analyzed for its DNA content, a variety of complex procedures must be performed. These include cell separation, washing, cell lysing and DNA or RNA purification. Current techniques for accomplishing this same series of procedures require extensive manual labor by skilled technicians and can take hours to several days. In the GeneXpert cartridge, fully automated sample preparation for a variety of samples can be accomplished in as little as five minutes.

With a prototype delivered to the U.S. Department of Defense at the end of last year and commercial availability slated for 2003, Cepheid's GeneXpert will deliver results from a sample in 30 minutes, enabling time-critical DNA tests at the point of need. Developed directly by Cepheid and through its partners, potential applications for the GeneXpert include clinical diagnostics, food testing, environmental testing and bio-threat detection.

Cepheid, based in Sunnyvale, Calif., is a leading developer, manufacturer and marketer of miniaturized, fully integrated systems for rapid, on-site detection of DNA -- the universal biological identifier. Founded in 1996, the company is commercializing its technology and products for scientific, medical and industrial applications requiring time-critical detection of human and other genes, infectious disease agents, and industrial and environmental contaminants at the point of need. Cepheid and GeneXpert are registered trademarks of Cepheid. See http://www.cepheid.com for more information.

Statements in this release, including new product plans and business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to Cepheid appears in Cepheid's reports filed with the U.S. Securities and Exchange Commission and available upon request from Cepheid. Cepheid disclaims any intent or obligation to update these forward-looking statements.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X36576656

SOURCE Cepheid

CONTACT: John Bishop, Chief Executive Officer, +1-408-541-4191, or bishop@cepheid.com, or Thomas Gutshall, Chairman, +1-408-541-4191, or gutshall@cepheid.com, both of Cepheid; or media, Yvonne Blaxter of Versaggi Biocommunications(R), +1-415-397-3087, or yvonne@versaggibio.com, for Cepheid

Copyright © 2002, PR Newswire

StockTrader Grandfathered

04/17/02 4:44 PM

Post #3

Cepheid Schedules First Quarter 2002 Financial Results and Conference Call

14:12 EDT Wednesday, April 17, 2002

SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) announced today plans to release its first quarter 2002 earnings after close of the stock market on Tuesday, April 23, 2002. In conjunction with the release, management will host a conference call the same day at 4:30 p.m. (Eastern). The call will be simultaneously broadcast over the Internet.

Interested participants may listen to a live webcast of the call on the investor relations section of Cepheid's web site at www.Cepheid.com. Web participants are encouraged to go to the web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. Listening to the webcast requires speakers and RealPlayer(TM) software, downloadable free at www.real.com.

During the call, Cepheid's Chairman, Tom Gutshall, Chief Executive Officer, John Bishop and Chief Financial Officer, Cathy Smith will discuss Cepheid's financial results, business highlights and future expectations. After the live webcast, the call will remain available on Cepheid's website www.Cepheid.com, through May 3, 2002.

Cepheid, based in Sunnyvale, Calif., is commercializing its I-CORE(R) technology as the preferred platform for rapid, on-site detection of DNA -- the universal biological identifier -- for scientific, medical and industrial applications. Sold directly and through its global network of partners, its Smart Cycler(R) family of products provides researchers with quantitative DNA analysis in real time, simultaneously supporting multiple users and protocols on a single instrument with results in less than 30 minutes. Enabling time-critical DNA test results at the point of need, Cepheid's next-generation GeneXpert(R) system provides the first automated integration of all the steps required to detect DNA from complex biological specimens -- sample preparation, amplification and detection. Cepheid, I-CORE, Smart Cycler and GeneXpert are registered trademarks of Cepheid.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X71631178

SOURCE Cepheid

CONTACT: Cathy Smith, Vice President and CFO of Cepheid, +1-408-541-4191

Copyright © 2002, PR Newswire

StockTrader Grandfathered

04/12/02 3:18 PM

Post #2

SUNNYVALE, Calif., Apr 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- Cepheid
(Nasdaq: CPHD) today announced the issuance of U.S. Patent 6,369,893 broadly
covering the company's fundamental I-CORE(R) module technology for simultaneous,
real-time optical excitation and detection of two or more nucleic acids, and
U.S. Patent 6,368,871 covering the automated preparation of biological samples
using chip-based microfluidics technology.

The inventors named in both patents include William A. McMillan, Cepheid vice
president of biotechnology; Kurt E. Petersen, Ph.D., president and chief
operating officer; and Lee A. Christel, Ph.D., vice president of engineering.

Cepheid has 36 U.S. patents issued or pending, plus corresponding foreign patent
applications. "These patents further strengthen Cepheid's intellectual property
and competitive barriers as we continue to expand our product line and grow our
market base," said Dr. Petersen.

I-CORE Technology

An integrated, cooling/heating, optical reaction system, the I-CORE module is at
the heart of every Cepheid DNA testing and analysis system. Each I-CORE module
contains its own heating and cooling components for rapid, precise temperature
control, and a four-channel optical analysis system capable of detecting and
quantifying up to four fluorescent dyes and multiple target molecules in
real-time. The module (which fits in the palm of your hand) is a complete,
independent fluorimeter for performing and continuously monitoring the
polymerase chain reaction (PCR) for amplifying DNA and other nucleic acids.

Cepheid's I-CORE patent covers an apparatus for "multiplex detection" -- the
simultaneous optical detection and analysis of two or more nucleic-acid targets
within the same reaction tube. Unlike other single or multiplex real- time
detection systems that use a single excitation light source and have limited
multiplexing capacity, Cepheid's unique I-CORE design includes multiple
excitation and detection sources for the widest range of multiplexing
capability, increasing test accuracy and information content.

The I-CORE module includes no moving parts and runs on low power, making it
highly durable and suitable for integration into portable and battery- powered
systems.

Automated Sample Preparation

Before a biological sample can be analyzed for its DNA content, a variety of
complex biochemical procedures must be performed. These include cell separation,
washing, cell lysing and DNA or RNA purification. Cepheid's microfluidics patent
broadly covers automated chip-based sample preparation for DNA, RNA, nucleic
acids, proteins and other biological samples. The technology is part of the tool
set for incorporation into Cepheid's DNA detection systems, including its
GeneXpert(R) system. The GeneXpert automates sample preparation, amplification
and detection, eliminating the need for skilled personnel.

With a prototype delivered to the U.S. Department of Defense at the end of last
year and commercial availability slated for 2003, Cepheid's GeneXpert provides
results from a raw sample in 30 minutes, enabling time-critical DNA tests at the
point of need. Current techniques for accomplishing this same series of
procedures require extensive manual labor by skilled technicians and can take
hours to several days. Developed directly by Cepheid and through its partners,
potential applications for the GeneXpert include clinical diagnostics, food
testing, environmental testing and biodefense.

Cepheid, based in Sunnyvale, Calif., is a leading developer, manufacturer and
marketer of miniaturized, fully integrated systems for rapid, on-site detection
of DNA -- the universal biological identifier. Founded in 1996, the company is
commercializing its technology and products for scientific, medical and
industrial applications requiring time-critical detection of human and other
genes, infectious disease agents, and industrial and environmental contaminants
at the point of need. Cepheid, I-CORE and GeneXpert are registered trademarks of
Cepheid. See http://www.cepheid.com for more information.

Statements in this release, including those that may relate to product
performance and business prospects are forward-looking statements. Actual
results might differ materially from these statements due to risks and
uncertainties, including the impact of competitive products and pricing, market
acceptance of new products, market conditions and enforcement of intellectual
property rights. A more detailed description of these risks and other risks
applicable to Cepheid appears in Cepheid's reports filed with the U.S.
Securities and Exchange Commission and available upon request from Cepheid.
Cepheid disclaims any intent or obligation to update these forward- looking
statements.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X51351366

SOURCE Cepheid

CONTACT: company, Thomas Gutshall, CEO & Chairman of Cepheid,

+1-408-541-4191 or gutshall@cepheid.com; or, media, Yvonne Blaxter of Versaggi

Biocommunications(R), +1-415-397-3087 or yvonne@versaggibio.com, for Cepheid

URL: http://www.cepheid.com

http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

KEYWORD: California

INDUSTRY KEYWORD: MTC

BIO

jmhollen

12/17/01 10:03 PM

Post #1

Cepheid Delivers GeneXpert(TM) to USAMRIID U.S. Army Research Unit Receives Prototype of First Instrument to Provide 'Walk-Away' DNA Testing

SUNNYVALE, Calif., Dec 17, 2001 /PRNewswire via COMTEX/ -- Cepheid (Nasdaq:
CPHD) today announced that it has delivered the first prototype of its
GeneXpert(TM) DNA detection system to the U.S. Army Medical Research Institute
of Infectious Diseases (USAMRIID) at Ft. Detrick, Maryland. Developed in part
with Department of Defense (DOD) funding, the GeneXpert system is the first
PCR-based instrument to fully automate all of the steps required for DNA
detection -- sample preparation, amplification and detection. Utilizing
Cepheid's patented technologies, the system will enable minimally trained
operators to obtain a DNA result, from a raw sample in under 30 minutes when and
where needed.

"The completion of this phase of the GeneXpert program marks the realization of
a joint strategic vision with the U.S. Army dating back to 1996," said USAMRIID
Col. Erik A. Henchal, Chief, Diagnostic Systems. "Providing 'walk-away' testing,
the GeneXpert system will greatly simplify DNA testing in a way that no other
instrument has been able to achieve. By performing all the preparation and
analysis in a single, closed cartridge, this system will improve our ability to
rapidly detect, not only bioterrorism agents, but other infectious organisms as
well."

The GeneXpert DNA-detection technology utilizes the polymerase chain reaction
(PCR), a method for amplifying a target DNA sequence to sufficient levels for
detection. Cepheid is the only company to have developed a PCR-based instrument
that integrates and automates all the DNA detection and analysis steps within a
preloaded, test-specific cartridge. Cepheid's GeneXpert system is slated for
commercial availability in the clinical diagnostics market in 2003.

Tom Gutshall, CEO and chairman said, "The delivery of a GeneXpert working
prototype to USAMRIID represents a major milestone for Cepheid. We are now in a
position to develop specific test applications for the GeneXpert with our key
collaborators in clinical diagnostics, agriculture, and food and beverage
quality testing. Making time-critical pathogen detection a reality, the
GeneXpert will put fast, highly accurate, and user-friendly DNA testing into the
hands of physicians, quality control technicians and other specialists for the
very first time."

Kurt Petersen, Ph.D., Cepheid's COO and president, added, "Achieving this
milestone is a testimony to the dedication and commitment of our Cepheid team.
Coupled with our emerging reagent technology, the GeneXpert platform will be a
strong, competitive entry into the DNA testing market."

Cepheid, based in Sunnyvale, Calif., is a leading developer, manufacturer and
marketer of miniaturized, fully integrated instrument systems for rapid, on-site
detection of DNA -- the universal biological identifier. Founded in 1996, the
company is commercializing its technology and products for scientific, medical
and industrial applications requiring time-critical detection of human and other
genes, infectious disease agents, and industrial and environmental contaminants
at the point of need.

Sold directly and through its global partners, its Smart Cycler(R) family of
products provides researchers with quantitative DNA analysis in real time,
simultaneously supporting multiple users and protocols on a single instrument
with results in less than 30 minutes. Cepheid's next-generation GeneXpert(TM)
system will provide the first automated integration of all the steps required to
detect DNA from complex biological specimens-sample preparation, amplification
and detection. Cepheid, Smart Cycler and GeneXpert are registered trademarks of
Cepheid. See www.cepheid.com for more information.

USAMRIID is the lead medical laboratory for the U.S. Army Biological Defense
research program, and plays a key role in national defense and in infectious
disease research. The Institute's mission is to develop medical countermeasures,
specifically vaccines, drugs and diagnostics, to protect U.S. service members
from biological warfare agents and endemic infectious diseases. USAMRIID is a
subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

SOURCE Cepheid

CONTACT: Thomas Gutshall, CEO & Chairman of Cepheid, +1-408-541-4191
or
gutshall@cepheid.com
or media
Yvonne Blaxter of Versaggi Biocommunications(R), +1-415-397-3087
or
yvonne@versaggibio.com for Cepheid

URL: http://www.cepheid.com

.

"..Have you hugged your Grandkiddies today.."?? and...Merry Christmas everybody..!!

.